Nephrotic syndrome diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Nephrotic syndrome}} | {{Nephrotic syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{MJ}} | ||
== Overview == | == Overview == | ||
Revision as of 19:27, 29 May 2018
|
Nephrotic Syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Nephrotic syndrome diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Nephrotic syndrome diagnostic study of choice |
|
Risk calculators and risk factors for Nephrotic syndrome diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
Diagnostic Study of Choice
Study of choice
- Kidney biopsy is the gold standard test for the diagnosis of nephrotic syndrome.[1]
- This method will reveal the exac cause of proteinuria.
Relative contrandications are:
- Single kidney
- Anatomic kidney abnormalities
- Small size kidneys (less than 9 cm), indicative of end stage renal disease
- Renal tumor
- Multiple, bilateral cysts
- Active infection in the kidney or on the skin over the biopsy side
- Uncorrectable bleeding diathesis
- Severe uncontrolled hypertension
- Hydronephrosis
- Uncooperative patient